FDA panel approves outcomes claim for Vytorin

Tools

The FDA advisory panel reviewing a new indication for Merck's ($MRK) cholesterol fighter Vytorin gave the drug a nod for preventing cardiovascular problems in patients with kidney disease, but voted against the indication for kidney patients on dialysis. Report

Filed Under